SenzaGen AB

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0010219626
SEK
6.14
-0.1 (-1.6%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 193 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.32

stock-summary
Return on Equity

-12.83%

stock-summary
Price to Book

2.60

Revenue and Profits:
Net Sales:
13 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.33%
0%
0.33%
6 Months
20.39%
0%
20.39%
1 Year
-15.31%
0%
-15.31%
2 Years
-13.52%
0%
-13.52%
3 Years
-52.77%
0%
-52.77%
4 Years
-42.62%
0%
-42.62%
5 Years
-56.76%
0%
-56.76%

SenzaGen AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
84.20%
EBIT Growth (5y)
10.92%
EBIT to Interest (avg)
-21.13
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.63
Tax Ratio
2.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.32
EV to EBIT
-11.60
EV to EBITDA
-37.28
EV to Capital Employed
3.10
EV to Sales
2.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.74%
ROE (Latest)
-12.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by SenzaGen AB"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 15.63% vs 19.38% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 19.00% vs 11.24% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "57.70",
          "val2": "49.90",
          "chgp": "15.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-6.60",
          "chgp": "39.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.30",
          "chgp": "66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.30",
          "val2": "-7.50",
          "chgp": "-10.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.90",
          "val2": "-22.10",
          "chgp": "19.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-222.00%",
          "val2": "-295.60%",
          "chgp": "7.36%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
57.70
49.90
15.63%
Operating Profit (PBDIT) excl Other Income
-4.00
-6.60
39.39%
Interest
0.50
0.30
66.67%
Exceptional Items
-8.30
-7.50
-10.67%
Consolidate Net Profit
-17.90
-22.10
19.00%
Operating Profit Margin (Excl OI)
-222.00%
-295.60%
7.36%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 15.63% vs 19.38% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 19.00% vs 11.24% in Dec 2023

stock-summaryCompany CV
About SenzaGen AB stock-summary
stock-summary
SenzaGen AB
Pharmaceuticals & Biotechnology
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Company Coordinates stock-summary
Company Details
Medicon Village, Building 401, Scheelevagen 2 LUND None : 223 63
stock-summary
Tel: 46 46 275620046 46 2756200
stock-summary
Registrar Details